Fulgent Genetics, Inc.
For the period ended Jun 30, 2025. Filed Aug 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 trading arrangements
During thethree months ended June 30, 2025, noneof our directors or officers adopted or terminated “Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K. However, Ming Hsieh, our Chief Executive Officer, terminated a prepaid variable forward agreement, or the Prepaid Agreement, dated as of September 14, 2022, with an unaffiliated bank, which constitutes a “non‑Rule 10b5‑1 trading arrangement” as defined in Item 408 of Regulation S-K. Under the Prepaid Agreement, Mr. Hsieh pledged up to 0.8 million shares of our common stock, or the Pledged Shares. On June 9, 2025, Mr. Hsieh elected to terminate the arrangement. Upon the payment of $16.4 million, the Pledged Shares were no longer subject to the Prepaid Agreement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.